Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

Autor: Metcalf, Anagha Gogate, Bryan Bennett, Zia Poonja, Grant Stewart, Ana Medina Colmenero, Petr Szturz, Courtney Carrington, Clara Castro, Eric Gemmen, Ashley Lau, Alberto Carral Maseda, Eric Winquist, Virginia Arrazubi, Desiree Hao, Audrey Cook, Joaquina Martinez Galan, Lisardo Ugidos, David Fernández Garay, David Gutierrez Abad, Robert

Publikováno v: Cancers; Volume 15; Issue 14; Pages: 3552

This study examined the real-world use of nivolumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). This was a multinational retrospective study (VOLUME) assessing treatment effectiveness and safety out

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::38dfbd3764c31b0eeaca41ab0581e2f4

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Autor: Malcolm David Mason, Robin Millman, Alison Birtle, Duncan McLaren, David Matheson, Stephanie Gibbs, John Graham, Prabir Chakraborti, Mahesh K. B. Parmar, Joanna Gale, Matthew S. Simms, Melissa Gannon, John Wagstaff, Anna T.H. Tran, J. Martin Russell, Robert Hughes, Joe M. O'Sullivan, Santhanam Sundar, Omi Parikh, Beth Woods, Mymoona Alzouebi, Audrey Cook, Richard Cathomas, Angus Robinson, Eleftherios Sideris, Robert Jones, Robert W. Laing, Susannah Brock, Clive Peedell, Narayanan Srihari, Chris Parker, Shaun Tolan, Gerhardt Attard, Nicholas D. James, Matthew R. Sydes, Alastair W. S. Ritchie, Andrew Protheroe, Mark Sculpher, William Cross, David Tsang, George N. Thalmann, Rajaguru Srinivasan, John Staffurth, David P. Dearnaley

Publikováno v: Woods, B S, Sideris, E, Sydes, M R, Gannon, M R, Parmar, M K B, Alzouebi, M, Attard, G, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P R, Cook, A, Cross, W R, Dearnaley, D P, Gale, J, Gibbs, S, Graham, J D, Hughes, R, Jones, R J, Laing, R, Mason, M D, Matheson, D, McLaren, D B, Millman, R, O'Sullivan, J M, Parikh, O, Parker, C C, Peedell, C, Protheroe, A, Ritchie, A W S, Robinson, A, Russell, J M, Simms, M S, Srihari, N N, Srinivasan, R, Staffurth, J N, Sundar, S, Thalmann, G N, Tolan, S, Tran, A T H, Tsang, D, Wagstaff, J, James, N D & Sculpher, M J 2018, ' Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness ', European urology oncology, vol. 1, no. 6, pp. 449-458 . https://doi.org/10.1016/j.euo.2018.06.004
European Urology Oncology

Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs fai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2281fcf0ea5be2ac6317f225090278
https://doi.org/10.1016/j.euo.2018.06.004

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial

Autor: Hisham, Mehanna, Max, Robinson, Andrew, Hartley, Anthony, Kong, Bernadette, Foran, Tessa, Fulton-Lieuw, Matthew, Dalby, Pankaj, Mistry, Mehmet, Sen, Lorcan, O'Toole, Hoda, Al Booz, Karen, Dyker, Rafael, Moleron, Stephen, Whitaker, Sinead, Brennan, Audrey, Cook, Matthew, Griffin, Eleanor, Aynsley, Martin, Rolles, Emma, De Winton, Andrew, Chan, Devraj, Srinivasan, Ioanna, Nixon, Joanne, Grumett, C René, Leemans, Jan, Buter, Julia, Henderson, Kevin, Harrington, Christopher, McConkey, Alastair, Gray, Janet, Dunn, Mererid, Evans

Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8f9a742f7f62a9c70dd5f401210c7ca7
https://strathprints.strath.ac.uk/75921/1/Mehanna_etal_TL_2018_Radiotherapy_plus_cisplatin_or_cetuximab_in_low_risk_human_papillomavirus_positive_oropharyngeal_cancer.pdf

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

Autor: Catherine Lemon, Dorothy M. Gujral, Paul Sanghera, James P Morden, Emma Hall, M. Emson, Simon Gollins, Q van den Blink, Matthew Beasley, L. Fresco, Mererid Evans, L Luxon, S.A. Bhide, E. Wells, Katie L. Newbold, Costar Investigators, Christopher M. Nutting, E. De Winton, M. Sivaramalingam, Kevin J. Harrington, Audrey Cook, Stephanie Witts, M Joseph, N. N Srihari, M. Sydenham, R Mendes, Martin Robinson, J Simpson, Robin Prestwich, A Miah

Publikováno v: European Journal of Cancer

Purpose About 40–60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2407c2110c5387ab984356defec124f
https://pubmed.ncbi.nlm.nih.gov/30286418

Observed & experiential integration (OEI): Discovery and development of a new set of trauma therapy techniques

Autor: Audrey Cook, Richard A. Bradshaw, Marvin J. McDonald

Publikováno v: Journal of Psychotherapy Integration. 21:104-171

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fdd268ed4f6302454038974da5fbe30
https://doi.org/10.1037/a0023966